Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results
26 avr. 2019 16h05 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26 avr. 2019 16h05 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting
23 avr. 2019 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 23, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab
22 avr. 2019 16h34 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 avr. 2019 16h19 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 avr. 2019 16h05 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 12, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Appoints Nadia Dac as Chief Commercial Officer
08 avr. 2019 16h05 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference
02 avr. 2019 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at the Cowen and Company 39th Annual Health Care Conference
05 mars 2019 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash, March 05, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares
04 mars 2019 18h48 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., March 04, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...